Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98154173 | 9815417 | 3 | F | 20110426 | 20160706 | 20140114 | 20160729 | EXP | US-ROCHE-1033148 | ROCHE | 72.00 | YR | F | Y | 73.30000 | KG | 20160729 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98154173 | 9815417 | 1 | PS | Vismodegib | VISMODEGIB | 1 | Oral | LAST DOSE PRIOR TO SAE: 06 JUL 2011, TOTAL DOSE ADMINISTERED THIS COURSE | U | 203388 | 3150 | MG | CAPSULE | ||||||
| 98154173 | 9815417 | 2 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 4650 | MG | CAPSULE | |||||||
| 98154173 | 9815417 | 3 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 4650 | MG | CAPSULE | |||||||
| 98154173 | 9815417 | 4 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3150 | MG | CAPSULE | |||||||
| 98154173 | 9815417 | 5 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3150 | MG | CAPSULE | |||||||
| 98154173 | 9815417 | 6 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3150 | MG | CAPSULE | |||||||
| 98154173 | 9815417 | 7 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3150 | MG | CAPSULE | |||||||
| 98154173 | 9815417 | 8 | SS | Vismodegib | VISMODEGIB | 1 | Oral | U | 203388 | 3150 | MG | CAPSULE | |||||||
| 98154173 | 9815417 | 9 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | U | 0 | 100 | MG/M**2 | ||||||||
| 98154173 | 9815417 | 10 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | U | 0 | 75 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 98154173 | 9815417 | 1 | Small cell lung cancer |
| 98154173 | 9815417 | 9 | Small cell lung cancer |
| 98154173 | 9815417 | 10 | Small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 98154173 | 9815417 | OT |
| 98154173 | 9815417 | LT |
| 98154173 | 9815417 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 98154173 | 9815417 | Anaemia | |
| 98154173 | 9815417 | Lung infection | |
| 98154173 | 9815417 | Neutrophil count decreased | |
| 98154173 | 9815417 | Pleural effusion | |
| 98154173 | 9815417 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 98154173 | 9815417 | 1 | 20110413 | 20111007 | 0 | |
| 98154173 | 9815417 | 2 | 20110504 | 0 | ||
| 98154173 | 9815417 | 3 | 20110606 | 0 | ||
| 98154173 | 9815417 | 4 | 20110627 | 0 | ||
| 98154173 | 9815417 | 5 | 20110718 | 0 | ||
| 98154173 | 9815417 | 6 | 20110809 | 0 | ||
| 98154173 | 9815417 | 7 | 20110830 | 0 | ||
| 98154173 | 9815417 | 8 | 20110920 | 0 | ||
| 98154173 | 9815417 | 9 | 20110413 | 0 | ||
| 98154173 | 9815417 | 10 | 20110413 | 0 |